Lennon RP, Zgierska AE, Miller EL, Snyder B, Keshaviah A, Hu XC, Zhou H, Van Scoy LJ. Lower intent to comply with COVID-19 public health recommendations correlates to higher disease burden in following 30 days. South Med J. 2021 Dec;114(12):744-50. doi: 10.14423/SMJ.0000000000001332
Salahuddin M, Salamo O, Karanth S, Faiz SA, Estrada-Y-Martin RM, Cherian SV. Safety and incidence of complications associated with bronchoscopy in an obese population. Clin Respir J. 2021 Jun;15(6):670-5. doi: 10.1111/crj.13342
Lennon RP, Miller EL, Dong H, Rabago D, Zgierska A. Association of the US COVID-19 pandemic and attenuated influenza detection. South Med J. 2021 Jun;114(6):343. doi: 10.14423/SMJ.0000000000001254
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Bullard JT, Eberth JM, Arrington AK, Adams SA, Cheng X, Salloum RG. Timeliness of treatment initiation and associated survival following diagnosis of non-small-cell lung cancer in South Carolina. South Med J. 2017 Feb;110(2):107-13. doi: 10.14423/SMJ.0000000000000601
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Brodtkorb T, Zetterström O, Tinghög G. Cost-effectiveness of clean air administered to the breathing zone in allergic asthma. Clin Respir J. 2010;4(2):104-10.
Nguyen USDT, Rothman KJ, Demissie S, Jackson DJ, Lang JM, Ecker JL. Transfers among women intending a birth center delivery in the San Diego birth center study. J Midwifery Womens Health. 2009 Mar 1;54(2):104-10.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.